Video

Dr. Brown on the Promise of the ROCSAN Trial in Gynecologic Carcinosarcomas

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Jubilee Brown, MD, professor, director, Gynecologic Oncology, Levine Cancer Institute, Atrium Health, discusses the promise of the phase 2/3 ROCSAN trial (NCT03651206) in recurrent gynecologic carcinosarcomas.

    The multicenter ROCSAN trial is currently enrolling patients with metastatic or recurrent endometrial or ovarian carcinosarcoma who have received at least 1 line of prior chemotherapy. Patients are randomized 2:2:1 to niraparib (Zejula), niraparib plus dostarlimab, or physician’s choice chemotherapy.

    Although data have not yet emerged from the study, the combination of the PARP inhibitor niraparib and the anti–PD-1 monoclonal antibody dostarlimab is a promising treatment regimen for this patient population, Brown explains. Moreover, because the 3-arm trial is evaluating multiple regimens, the data will answer multiple questions regarding the treatment of patients with gynecologic carcinosarcomas, Brown concludes.

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data